90Y-Zevalin® (90Y-Ibritumomab Tiuxetan) Radioimmunotherapy (RIT) Consolidation of FCM Induction Chemotherapy in Mantle Cell Lymphoma (MCL) Patients: Results from the PLRG upon Completed Enrollment

Background: The 5-yr survival rate is

Saved in:
Bibliographic Details
Published in:Blood 2006-11, Vol.108 (11), p.2747-2747
Main Authors: Jurczak, Wojciech, Giza, A., Szostek, M., Hubalewska-Dydejczyk, A., Sowa-Staszczak, A., Knopinska-Posluszny, W., Hellmann, A., Zdziarska, B., Wrobel, T., Krycz-Krzemien, S., Poplawska, L., Federowicz, I., Walewski, Jan, Skotnicki, Aleksander
Format: Article
Language:English
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Background: The 5-yr survival rate is
ISSN:0006-4971
1528-0020
DOI:10.1182/blood.V108.11.2747.2747